BioHarvest Sciences top-line climbs 8% as CDMO segment doubles
BioHarvest Sciences (NASDAQ:BHST) reported steady growth for the first quarter of 2026, driven by a surge in its corporate contract services and the continued expansion of its flagship direct-to-consumer health products.






















